Objective. To explore the differential efficacy of chemoradiotherapy combined with adoptive immunotherapy and radiochemotherapy alone in patients with non-small-cell lung cancer (NSCLC). Methods. Qualified randomized controlled trial (randomized controlled trial, RCT), or nonrandomized concurrent controlled trial (NRCCT), published in various databases, including PubMed, EMBASE, Chinese journal full-text database, Medline, Cochrane database, and VIP Chinese database, and the Revman5. 0 software performed the data analysis. Results. We found the significantly different curative effect between the experimental and control groups ( OR = 1.94 , 95% CI (1.46, 2.58), P < 0.001 , I 2 = 0 % , Z = 4.59 ), effect of adoptive immunotherapy on the progression of disease ( OR = 1.80 , 95% CI (1.38, 2.35), P < 0.001 , I 2 = 0 % , Z = 4.33 ), adoptive immunotherapy on overall survival ( OR = 2.19 , 95% CI (1.60, 2.99), P < 0.001 , I 2 = 0 % , Z = 4.91 ), and adverse effects of adoptive immunotherapy ( OR = 1.76 , 95% CI (1.25, 2.48), P = 0.001 , I 2 = 0 % , Z = 3.26 ). Conclusion. Adoptive immunotherapy combined with microradiotherapy can decrease the recurrence of NSCLC and improve patient survival, as well as early patients can be benefited more significantly from immunotherapy.